PCM
STOK icon

Penserra Capital Management’s Stoke Therapeutics STOK Stock Holding History

Penserra Capital Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-88,507
Closed -$2.81M – 1175
2025
Q4 		$2.81M Sell
88,507
-62,092
-41% -$1.87M 0.03% 316
2025
Q3 		$3.54M Buy
+150,599
New +$2.58M 0.04% 292
2021
Q4 		– Sell
-840
Closed -$21K – 1540
2021
Q3 		$21K Buy
840
+5
+0.6% +$139 ﹤0.01% 1240
2021
Q2 		$28K Buy
835
+20
+2% +$707 ﹤0.01% 1103
2021
Q1 		$31K Sell
815
-15
-2% -$854 ﹤0.01% 901
2020
Q4 		$51K Buy
830
+544
+190% +$24.9K ﹤0.01% 684
2020
Q3 		$9K Buy
+286
New +$8.17K ﹤0.01% 825

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Penserra Capital Management's STOK Position: Q1 2026 in Review

Penserra Capital Management sold out of Stoke Therapeutics (STOK) in Q1 2026, closing a stake of 88,507 shares — an estimated $2.81M sold.

Penserra Capital Management first reported a position in STOK in Q3 2020 and held it in 7 quarters. The position peaked at $3.54M in Q3 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Penserra Capital Management reported no remaining Stoke Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Penserra Capital Management sold 88,507 Stoke Therapeutics shares in Q1 2026, an estimated $2.81M.
  • Penserra Capital Management first reported a position in Stoke Therapeutics in Q3 2020 and held it in 7 quarters.
  • Penserra Capital Management's Stoke Therapeutics position peaked at $3.54M in Q3 2025.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Penserra Capital Management's 13F filing for Q1 2026, filed 11 May 2026.